ARCB three-lens brief
Evidence-based stock research on ARCB. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · P/E of 106 — priced for high growth; little margin of safety.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- P/E of 106 — priced for high growth; little margin of safety.
- Analyst mean target $167.15 — 23% above current (13 analysts).
- Reported earnings on 2026-11-04.
- Ex-dividend date 2026-11-13.
ARCB closed at $135.91 (+1.54%) as of 2026-11-12. Market cap: $3.00B. P/E (trailing) 106.2. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; analyst mean target $167.15 — 23% above current (13 analysts).. Concerns: p/E of 106 — priced for high growth; little margin of safety.. Last quarter: Revenue $1.21B, net income $51.66M, free cash flow $266.52M.
Why three lenses on ARCB, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ARCB across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ARCB" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ARCB brief"></iframe>